-
21.
公开(公告)号:CY1111977T1
公开(公告)日:2015-11-04
申请号:CY111100375
申请日:2011-04-12
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: DE BRUYN MARCEL FRANS LEOPOLD , MACDONALD GREGOR JAMES , KENNIS LUDO EDMOND JOSEPHINE , LANGLOIS XAVIER JEAN MICHEL , VAN DEN KEYBUS FRANS ALFONS MARIA , VAN ROOSBROECK YVES EMIEL MARIA
IPC: C07D401/12 , A61K31/501 , A61P25/00 , C07D409/14
Abstract: Ηπαρούσαεφεύρεσηαναφέρεταισεενώσειςπουείναιταχέωςδιασπόμενοιανταγωνιστέςυποδοχέωνντοπαμίνης 2, διαδικασίεςγιατηνπαρασκευήαυτώντωνενώσεων, φαρμακευτικέςσυνθέσειςπουπεριλαμβάνουναυτέςτιςενώσειςωςενεργόσυστατικό. Οιενώσειςβρίσκουνχρησιμότηταωςφάρμακαγιατηθεραπείαή τηνπρόληψηδιαταραχώντουκεντρικούνευρικούσυστήματος, γιαπαράδειγμασχιζοφρένεια, προκαλώνταςμίααντιψυχωτικήεπίδρασηχωρίςκινητικέςπαρενέργειες.
-
公开(公告)号:BRPI0912196A2
公开(公告)日:2015-10-06
申请号:BRPI0912196
申请日:2009-05-08
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/455 , A61P25/00 , C07D231/38 , C07D401/04 , C07D407/04 , C07D407/14
-
公开(公告)号:ZA201206715B
公开(公告)日:2015-04-29
申请号:ZA201206715
申请日:2012-09-07
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: BARTOLOME-NEBREDA JOSE MANUEL , MACDONALD GREGOR JAMES , VAN GOOL MICHIEL LUC MARIA , VANHOOF GRETA CONSTANTIA PETER , CONDE-CEIDE SUSANA , PASTOR-FERNANDEZ JOAQUIN , MARTIN-MARTIN MARIA LUZ
IPC: A61K20060101 , A61P20060101 , C07D20060101
Abstract: The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.
-
公开(公告)号:ZA201204433B
公开(公告)日:2014-11-26
申请号:ZA201204433
申请日:2012-06-15
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: MACDONALD GREGOR JAMES , CONDE-CEIDE SUSANA , BARTOLOME-NEBREDA JOSE MANUEL , TRABANCO-SUAREZ ANDRES AVELINO , TRESADERN GARY JOHN , PASTOR-FERNANDEZ JOAQUIN
IPC: A61K20060101 , A61P20060101 , C07D20060101
Abstract: The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.
-
公开(公告)号:ES2501946T3
公开(公告)日:2014-10-02
申请号:ES07728289
申请日:2007-04-19
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: THURING JOHANNES WILHELMUS JOHN F , MACDONALD GREGOR JAMES , LESAGE ANNE SIMONE JOSEPHINE , ZHUANG WEI , DE BRUYN MARCEL FRANS LEOPOLD , VAN DEN KEYBUS FRANS ALFONS MARIA , VAN ROOSBROECK YVES EMIEL MARIA , DINKLO THEODORUS , DUFFY JAMES EDWARD STEWART
IPC: C07D401/04
Abstract: Compuesto según la fórmula (I) incluyendo todas las formas estereoquímicamente isoméricas del mismo, en la que: Z es alquilo C1-6 o alquilo C1-6 sustituido con uno o más sustituyentes independientemente seleccionados del grupo que consiste en hidroxilo, ciano, (alquil C1-6)-O-, R1R2N-C(>=O)-, R7-O-C(>=O)-NR8-, R10-O-C(>=O)-, R3-C(>=O)-NR4 -, HO-N-C(>=NH)-, halo, oxo, polihaloalquilo C1-6 y Het; Q es fenilo, piridinilo, benzodioxolilo, en el que cada radical está opcionalmente sustituido con uno, dos o tres sustituyentes cada uno independientemente seleccionado del grupo que consiste en halo, ciano, alquilo C1-6, (alquil C1-6)-O-, polihalo-alquilo C1-6, polihalo(alquil C1-6)-O-, y mono- o di(alquil C1-6)amino; L es piridinilo, benzodioxolilo, indolinilo, quinolinilo, 2,3-dihidropirrolopiridinilo, furopiridinilo, benzodioxanilo, dihidrofuropiridinilo, 7-azaindolinilo, 3,4-dihidro-2H-1,4-benzoxazinilo; en el que cada radical está opcionalmente sustituido con uno o dos o más sustituyentes, seleccionándose cada sustituyente independientemente del grupo que consiste en halo, ciano, alquilo C1-6, (alquil C1-6)-O-, polihaloalquilo C1-6, HO-alquilo C1-6-, polihalo-(alquil C1-6)-O-, amino-alquilo C1-6-, mono- o di(alquil C1-6)amino, R15R16N-C(>=O)-, morfolinilo, CH3O-(alquil C1-6)-NH-, HO-(alquil C1- 6)-NH-, benciloxilo, cicloalquilo C3-6, (cicloalquil C3-6)-NH-, (cicloalquil C3-6)-(alquil C1-6)-NH-, polihalo(alquil C1-6)- C(>=O)-NR14-, (alquil C1-6)-C(>=O)-, y (alquil C1-6)-O-(alquil C1-6)-; R1 y R2 representan cada uno independientemente hidrógeno, alquilo C1-6, cicloalquilo C3-6, (alquil C1-4)-O-alquilo C1- 6, Het2, HO-alquilo C1-6, polihaloalquilo C1-6, cicloalquilo C3-6 sustituido con alquilo C1-4, (cicloalquil C3-6)-alquilo C1-6, dimetilamino-alquilo C1-4 o 2-hidroxiciclopentan-1-ilo; o R1 y R2 tomados junto con el átomo de nitrógeno al que están unidos forman un radical heterocíclico seleccionado del grupo que consiste en pirrolidinilo, y morfolinilo; R3 representa hidrógeno, alquilo C1-6, cicloalquilo C3-6, o Het3; R4 y R8 representan cada uno independientemente hidrógeno o alquilo C1-6; R6 representa hidrógeno, o cuando Q representa fenilo, R6 también puede ser un alcanodiilo C2-6 unido a dicho anillo de fenilo para formar junto con el nitrógeno al que está unido y dicho anillo de fenilo, indolinilo sustituido con trifluorometilo; R7 y R10 representan cada uno independientemente alquilo C1-6 o cicloalquilo C3-6; R11 y R14 representan cada uno independientemente hidrógeno o alquilo C1-6; R15 y R16 representan cada uno independientemente hidrógeno o alquilo C1-6; o R15 y R16 tomados junto con el átomo de nitrógeno al que están unidos pueden formar pirrolidinilo; Het y Het1 representan cada uno independientemente oxazolilo opcionalmente sustituido con alquilo C1-6; Het2 representa tetrahidrofuranilo; Het3 representa oxazolilo; un N-óxido, una sal de adición farmacéuticamente aceptable, un solvato o una amina cuaternaria del mismo.
-
26.
公开(公告)号:CA2665924C
公开(公告)日:2014-08-12
申请号:CA2665924
申请日:2007-12-05
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: MACDONALD GREGOR JAMES , ANDRES-GIL JOSE IGNACIO , VAN DEN KEYBUS FRANS ALFONS MARIA , BARTOLOME-NEBREDA JOSE MANUEL , VAN GOOL MICHIEL LUC MARIA
IPC: C07D401/12 , A61K31/501 , A61P25/18
Abstract: The present invention relates to 6-(piperidin-4-ylamino)pyridazin-3-carbonitriles of formula (I) that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.
-
27.
公开(公告)号:ZA201209296B
公开(公告)日:2014-05-28
申请号:ZA201209296
申请日:2012-12-07
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TRABANCO-SUAREZ ANDRES AVELINO , MACDONALD GREGOR JAMES , TRESADERN GARY JOHN , VEGA RAMIRO JUAN ANTONIO
IPC: A61P20060101 , A61K20060101 , C07D20060101
Abstract: The present invention relates to novel 5-amino-3,6-dihydro-1H-pyrazin-2-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.
-
公开(公告)号:BRPI0807492A2
公开(公告)日:2014-05-27
申请号:BRPI0807492
申请日:2008-02-11
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: MACDONALD GREGOR JAMES , LANGLOIS XAVIER JEAN MICHEL , BARTOLOME-NEBREDA JOSE MANUEL , GOOL MICHIEL LUC MARIA VAN
IPC: C07D237/20 , A61K31/495 , A61P25/18 , C07D237/24 , C07D409/04 , C07D487/04
Abstract: The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.
-
公开(公告)号:HK1182098A1
公开(公告)日:2013-11-22
申请号:HK13109367
申请日:2013-08-09
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TRABANCO-SUREZ ANDRS AVELINO , ROMBOUTS FREDERIK JAN RITA , TRESADERN GARY JOHN , GOOL MICHIEL LUC MARIA VAN , MACDONALD GREGOR JAMES , MARTINEZ LAMENCA CAROLINA , GIJSEN HENRICUS JACOBUS MARIA
IPC: C07D20060101 , A61K20060101 , A61P20060101
Abstract: The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.
-
公开(公告)号:CL2012003427A1
公开(公告)日:2013-04-01
申请号:CL2012003427
申请日:2012-12-05
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: MACDONALD GREGOR JAMES , TRABANCO SUAREZ ANDRES AVELINO , TRESADERN GARY JOHN , VEGA RAMIRO JUAN ANTONIO
IPC: C07D401/10 , A61K31/4965 , A61P25/16 , A61P25/28 , C07D401/12 , C07D403/10
Abstract: Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como Alzheimer, senilidad, demencia, entre otras.
-
-
-
-
-
-
-
-
-